Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on March 27, 2013. The report discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The material change reported is the election of a new director:
- Matthew L. Posard was elected to the Board of Directors on March 27, 2013.
- He was elected to the Class I of directors with a term ending in 2014.
- He will stand for election by stockholders at the 2014 annual meeting.
- The specific Board committee(s) for Mr. Posard have not yet been determined.
Guidance, Outlook, and Compensation
Mr. Posard will receive compensation under the director compensation program applicable to all non-employee directors. This currently consists of cash retainers for Board and committee service and restricted stock awards. The filing contains no guidance, outlook, management commentary on operations, risks, or contingencies.
Investor Verification Checklist
- Verify the biographical background and potential conflicts of interest for the newly elected director, Matthew L. Posard.
- Confirm the specific committee assignments for Mr. Posard once determined by the Board.
- Review the company's proxy statement for the 2014 annual meeting regarding the upcoming stockholder vote on Mr. Posard's election.